Financial Highlights
- Net Sales: ¥48.55B
- Operating Income: ¥-1.43B
- Net Income: ¥-1.06B
- EPS: ¥-36.67
Income Statement
| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥48.55B | ¥46.82B | +3.7% |
| Cost of Sales | ¥9.36B | ¥9.09B | +2.9% |
| Gross Profit | ¥39.20B | ¥37.73B | +3.9% |
| SG&A Expenses | ¥40.63B | ¥37.94B | +7.1% |
| Operating Income | −¥1.43B | −¥217M | −559.0% |
| Non-operating Income | ¥195M | ¥222M | −12.2% |
| Non-operating Expenses | ¥309M | ¥236M | +30.9% |
| Ordinary Income | −¥1.54B | −¥231M | −568.8% |
| Profit Before Tax | −¥1.66B | −¥231M | −617.7% |
| Income Tax Expense | −¥596M | ¥892M | −166.8% |
| Net Income | −¥1.06B | −¥1.12B | +5.5% |
| Net Income Attributable to Owners | −¥1.06B | −¥1.12B | +5.5% |
| Total Comprehensive Income | −¥922M | −¥1.49B | +38.0% |
| Depreciation & Amortization | ¥510M | ¥527M | −3.2% |
| Interest Expense | ¥108M | ¥68M | +58.8% |
| Basic EPS | −¥36.67 | −¥39.18 | +6.4% |
Balance Sheet
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥25.01B | ¥23.87B | +¥1.14B |
| Cash and Deposits | ¥8.77B | ¥9.16B | −¥392M |
| Accounts Receivable | ¥4.28B | ¥5.04B | −¥754M |
| Inventories | ¥7.82B | ¥6.31B | +¥1.51B |
| Non-current Assets | ¥9.85B | ¥8.78B | +¥1.07B |
| Property, Plant & Equipment | ¥4.76B | ¥4.70B | +¥66M |
| Intangible Assets | ¥95M | ¥120M | −¥25M |
| Goodwill | ¥45M | ¥71M | −¥26M |
| Investment Securities | ¥2.72B | ¥2.45B | +¥271M |
| Total Assets | ¥34.86B | ¥32.65B | +¥2.21B |
| Current Liabilities | ¥24.10B | ¥20.00B | +¥4.09B |
| Accounts Payable | ¥1.59B | ¥1.92B | −¥336M |
| Short-term Loans | ¥16.40B | ¥11.40B | +¥5.00B |
| Non-current Liabilities | ¥673M | ¥1.10B | −¥423M |
| Long-term Loans | ¥251M | ¥671M | −¥420M |
| Total Liabilities | ¥24.77B | ¥21.10B | +¥3.67B |
| Total Equity | ¥10.08B | ¥11.55B | −¥1.46B |
| Capital Stock | ¥2.04B | ¥2.04B | ¥0 |
| Capital Surplus | ¥1.81B | ¥1.81B | ¥0 |
| Retained Earnings | ¥5.92B | ¥7.69B | −¥1.77B |
| Treasury Stock | −¥26M | −¥195M | +¥169M |
| Owners' Equity | ¥10.08B | ¥11.55B | −¥1.46B |
| Working Capital | ¥907M | - | - |
Cash Flow Statement
| Item | Current | Prior | Change |
|---|---|---|---|
| Operating Cash Flow | −¥3.56B | −¥982M | −¥2.58B |
| Investing Cash Flow | −¥680M | −¥679M | −¥1M |
| Financing Cash Flow | ¥3.85B | −¥3.65B | +¥7.50B |
| Free Cash Flow | −¥4.24B | - | - |
Profitability Ratios
| Item | Value |
|---|---|
| Net Profit Margin | −2.2% |
| Gross Profit Margin | 80.7% |
| Current Ratio | 103.8% |
| Quick Ratio | 71.3% |
| Debt-to-Equity Ratio | 2.46x |
| Interest Coverage Ratio | −13.24x |
| EBITDA Margin | −1.9% |
| Effective Tax Rate | 35.9% |
Year-over-Year Comparison
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | +3.7% |
Share Information
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 29.08M shares |
| Treasury Stock | 36K shares |
| Average Shares Outstanding | 28.96M shares |
| Book Value Per Share | ¥347.20 |
| EBITDA | −¥920M |
Dividend Information
| Item | Amount |
|---|---|
| Q2 Dividend | ¥12.50 |
Segment Information
| Segment | Revenue | Operating Income |
|---|---|---|
| BioDirectValue | ¥42.73B | −¥342M |
| BioFunctionalSeeds | ¥5.56B | ¥858M |
| BioMedical | ¥230M | −¥473M |
| OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusiness | ¥30M | −¥14M |
Full Year Forecast
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥67.00B |
| Operating Income Forecast | ¥2.00B |
| Ordinary Income Forecast | ¥2.00B |
| Net Income Attributable to Owners Forecast | ¥1.50B |
| Basic EPS Forecast | ¥51.65 |
| Dividend Per Share Forecast | ¥25.00 |